Europe Cancer Biomarkers Market Trends

Lung cancer is caused by the uncontrolled growth of abnormal cells that multiply in one lung or both lungs. Although it can affect people who never smoked, people who smoke have the highest risk of lung cancer. The risk of lung cancer increases with the duration and number of cigarettes that the patient smoked. Other risk factors include occupational or environmental exposure to secondhand smoke, asbestos, certain metals, some organic chemicals, radiation, air pollution, and diesel exhaust.

With the rising cancer cases, there are millions of people that are being infected with COVID-19 around the globe. Since the focus of healthcare facilities was shifted to COVID-19, cancer patients' treatment was restricted for a certain period, followed by cancer biomarker-related clinical trials were being halted for a less period of time that showed a slight negative impact on the overall market.

According to the estimates of Globocan 2020, there were 457,960 new cancer cases in the United Kingdom, while prostate, breast, lung, colon, and skin cancer are the most common types of cancer detected in the United Kingdom. Based on the same estimates, there were 415,269 new cases of cancer in Italy and about 174,759 deaths. Therefore, owing to the rising number of cases of cancer, the cancer biomarkers market in Europe is expected to record substantial growth over the forecast period.

Some of the leading biomarkers for lung cancer include CYFRA 21-1, Plasma Kallikrein (KLKB1), Serum Amyloid A (SAA), Haptoglobin β Chain (Hp β), Complement Component 9 (C9), Endoglin (CD105), Peroxiredoxin 1 (PRX1), and Pro-gastrin-releasing Peptide (proGRP). As most of the aforementioned biomarkers are commercially available, the intensity of competition is already high in this segment. Therefore, the early diagnosis, coupled with the rising level of awareness among people, may lead to the healthy growth of the market studied.